Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechNSE:CONCORDBIO -0.34%89 Gross Margin % is 78.92% as of Jun. 2026, which is 5% above its 10-year median of 75.15. GuruFocus rates NSE:CONCORDBIO with a GF Score™ of 89/100 and a GF Value™ of ₹1,681.38 (Fairly Valued). The stock has 6 warning signs investors should review. Among 735 Biotechnology companies, Concord Biotech ranks better than 67.48% on this metric.
Concord Biotech Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.1%.
The historical rank and industry rank for Concord Biotech's Gross Margin % or its related term are showing as below:
NSE:CONCORDBIO'
s Gross Margin % Range Over the Past 10 Years
Min: 72.41 Med: 75.15 Max: 80.08
Current: 77.01
During the past 7 years, the highestGross Margin % of Concord Biotech was 80.08%. The lowest was 72.41%. And the median was 75.15%.
NSE:CONCORDBIO's Gross Margin % is ranked better than 67.48% of 735
companies
in the Biotechnology industry
Industry Median: 60.91
vs NSE:CONCORDBIO: 77.01
Concord Biotech had a gross margin of 78.92% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Concord Biotech was -1.10% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Concord Biotech had a gross margin of 78.92% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Concord Biotech Gross Margin % Related Terms
Concord Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CONCORDBIO vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Concord Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Concord Biotech (NSE:CONCORDBIO) has a Gross Margin % of 78.92% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Biotech and its competitors. This is near median its historical median of 75.15. Over the past decade, Concord Biotech's Gross Margin % has ranged from 72.41 to 80.08. According to the industry distribution chart, Concord Biotech ranks #239 out of 735 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Concord Biotech's Gross Margin % too high?
Concord Biotech's current Gross Margin % of 78.92% is near median its 10-year median of 75.15. Over the past 10 years, this metric has ranged from a low of 72.41 to a high of 80.08. The Biotechnology industry median Gross Margin % is 60.91. Concord Biotech's value of 78.92% is 29.6% above this industry median. Based on the distribution chart, Concord Biotech ranks #239 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #239 out of 735 companies for Gross Margin %. This puts Concord Biotech in the upper half of its industry. The industry median Gross Margin % is 60.91. Concord Biotech's value of 78.92% is 29.6% above this benchmark. Historically, Concord Biotech's own Gross Margin % has ranged from 72.41 to 80.08 over the past decade. While the company's 10-year median is 75.15 vs. the industry median of 60.91, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Gross Margin % of 78.92% is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Gross Margin % is 78.92%, which is near median its own 10-year median of 75.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (NSE:CONCORDBIO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,681.38, compared to a current price of ₹1,571.30 — trading 6.5% below its estimated fair value. The current Gross Margin % is 78.92%, which is near median its 10-year median of 75.15 and 29.6% above the Biotechnology industry median of 60.91. Concord Biotech's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Concord Biotech (NSE:CONCORDBIO), the current Gross Margin % is 78.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (NSE:CONCORDBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,571.30 is trading 6.5% below its estimated GF Value™ of ₹1,681.38.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for NSE:CONCORDBIO:
Gross Margin %: 78.92% (near median its 10-year median of 75.15)
GF Value™: ₹1,681.38 vs. price of ₹1,571.30 (6.5% below fair value)
Industry Position: 29.6% above the Biotechnology median (#239 of 735)
No single metric tells the full story. See the NSE:CONCORDBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for NSE:CONCORDBIO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CONCORDBIO has been successfully added to your 
